deltatrials
Completed PHASE1 NCT00221325

A Safety Study of Rituximab Plus MTX Injected Into the Cerebrospinal Fluid in the Treatment of Brain Lymphoma

Phase I Study of Intraventricular Administration of Rituximab in Combination With Methotrexate in the Treatment of Recurrent CNS and Intraocular Lymphoma

Sponsor: University of California, San Francisco

Conditions Central Nervous System Lymphoma Intraocular Lymphoma
Interventions Intraventricular Rituximab Plus MTX
Updated 6 times since 2017 Last updated: Feb 12, 2015 Started: Apr 30, 2007 Primary completion: Jan 31, 2012 Completion: Mar 31, 2013

This PHASE1 trial investigates Central Nervous System Lymphoma and Intraocular Lymphoma and is currently completed. University of California, San Francisco leads this study, which shows 6 recorded versions since 2007 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE1

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE1

    First recorded

Apr 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • University of California, San Francisco
Data source: University of California, San Francisco

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Boston, United States
  • • Houston, United States
  • • New York, United States
  • • San Francisco, United States